Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
29 Results for "
medullary thyroid carcinoma
" in MedChemExpress (MCE) Product Catalog:
Products (29)
29 Results for "medullary thyroid carcinoma" in MCE Product Catalog:
Cat. No.: HY-W009776
CAS No.: 38937-66-5
Synonyms: Suberohydroxamic acid; SBHA
Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive and cell-permeable HDAC1 and HDAC3 inhibitor with ID50 values of 0.25 μM and 0.30 μM, respectively .Suberoyl bis-hydroxamic acid renders MM cells susceptible to apoptosis and facilitates the mitochondrial apoptotic pathways .Suberoyl bis-hydroxamic acid can be used for the study of medullary thyroid carcinoma (MTC) .
Target:
Research Areas:
NSC194598 is a p53 DNA-binding inhibitor with an IC50 value of 180 nM. NSC194598 inhibits p53 DNA binding and induction of target genesn when p53 is stabilized and activated by irradiation or chemotherapy. NSC194598 can interfere with transcriptional activation of mutated rearranged during transfection (RET) gene, induce apoptosis and G0/G1 phase arrest. NSC194598 can be used for the researches of acute radiation toxicity and medullary thyroid carcinoma .
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .
Cat. No.: HY-148745
CAS No.: 2241517-83-7
Target:
Research Areas:
JG-258 is an inactive negative control for Hsp70 inhibitors. JG-258 is an inactive structural analog of JG-98 (HY-117282), an allosteric inhibitor of heat shock protein 70 (Hsp70) with demonstrated anticancer activity. JG-258 can be used in cancer-related research .
Cat. No.: HY-164725
CAS No.: 3023869-94-2
Research Areas:
Cat. No.: HY-170855A
Research Areas:
YW-N-7 TFA is a PROTAC degrader targeting RET kinase, with an IC50 of 8.4 nM. YW-N-7 TFA inhibits RET kinase activity and induces proteasome-mediated degradation of RET fusion proteins, while enhancing the anti-tumor activity of Selpercatinib (LOXO-292) (HY-114370). YW-N-7 TFA can be used in the research of cancers associated with RET gene abnormalities, including medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer .
Cat. No.: HY-183729
CAS No.: 2222758-09-8
Research Areas:
RET-IN-34 is a RET inhibitor with an IC50 of 0.89 nM. RET-IN-34 serves as a target protein ligand for PROTAC synthesis (Ligand for Target Protein for PROTAC). RET-IN-34 is applicable for the synthesis of PROTAC RET Degrader 2 (HY-183783). RET-IN-34 exhibits anticancer activity against medullary thyroid carcinoma. RET-IN-34 can be used in studies related to medullary thyroid carcinoma .
Cat. No.: HY-183783
PROTAC RET Degrader 2 is a RET degrader with a target IC50 of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma .
Cat. No.: HY-183684
RET-IN-33 is a moderately selective inhibitor of RET mutants. RET-IN-33 potently inhibits G810 mutants, with IC50 values of 4.43 nM (G810R), 3.28 nM (G810C) and 0.51 nM (G810S), respectively. RET-IN-33 also inhibits other RET mutants: V804M (IC50 0.73 nM), V804L (IC50 0.36 nM), Y806H (IC50 0.74 nM) and M918T (IC50 0.55 nM). RET-IN-33 also inhibits other kinases, with an IC50 of 1.50 nM against VEGFR2 and 1.60 nM against PDGFRα. RET-IN-33 blocks the autophosphorylation of RET mutants and the downstream SHC/AKT/ERK signaling pathway. RET-IN-33 selectively inhibits the proliferation of RET-driven cell models without affecting non-RET-dependent or normal cells. RET-IN-33 exhibits dose-dependent antitumor efficacy in RET-driven xenograft models. RET-IN-33 can be used for the research of medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer .
Cat. No.: HY-P73679
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
HEK293
Cat. No.: HY-P702542
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P73678
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P705868
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P705869
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P705870
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P705871
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P705872
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P705873
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RET; Cadherin Family Member 12; Prev. HSCR1; RET51; Prev. MEN2A; Ret Proto-Oncogene (Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1, Hirschsprung Disease); Prev. MEN2B; Multiple Endocrine Neoplasia And medullary thyroid carcinoma 1; Prev.
Species:
Human
Source:
sf9 insect cells
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
